Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Risedronate].

Masao Fukunaga1

  • 1Department of Nuclear Medicine, Kawasaki Medical School.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 18, 2003
PubMed
Summary
This summary is machine-generated.

Risedronate (RSD), a nitrogen-containing bisphosphonate, effectively treats osteoporosis by increasing bone mineral density and reducing fractures. Dosage varies between Japanese and Caucasian populations, suggesting differences in absorption.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating α-Klotho Counteracts Transforming Growth Factor-β-Induced Sarcopenia.

The American journal of pathology·2023
Same author

Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene.

Calcified tissue international·2023
Same author

Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association·2020
Same author

Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.

Current medical research and opinion·2020
Same author

Executive summary of the Japan Osteoporosis Society Guide for the Use of Bone Turnover Markers in the Diagnosis and Treatment of Osteoporosis (2018 Edition).

Clinica chimica acta; international journal of clinical chemistry·2019
Same author

Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.

Journal of bone and mineral metabolism·2018

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Geriatric Medicine

Background:

  • Risedronate (RSD) is a third-generation nitrogen-containing bisphosphonate.
  • It exhibits potent antiresorptive activity with minimal inhibition of mineralization.
  • RSD is a key therapeutic agent for osteoporosis management.

Purpose of the Study:

  • To summarize the efficacy and dosing of Risedronate (RSD) in osteoporosis treatment.
  • To highlight the observed differences in effective oral dosage between Japanese and Caucasian populations.
  • To underscore the role of RSD in reducing fracture risk.

Main Methods:

  • Review of clinical data on Risedronate (RSD) efficacy and safety.
  • Analysis of bone mineral density changes in osteoporotic patients.

Related Experiment Videos

  • Evaluation of fracture reduction data in elderly osteoporotic women.

    • Main Results:

    • Oral Risedronate (RSD) at 2.5 mg daily for 48 weeks increased lumbar spine bone mineral density by 5% in osteoporotic women.
    • A daily dose of 5 mg RSD decreased vertebral and non-vertebral fractures, particularly hip fractures, in elderly osteoporotic women.
    • Effective oral dosage differs between Japanese (2.5 mg) and Caucasian (5 mg) populations, implying varied absorption rates.

    Conclusions:

    • Risedronate (RSD) is an effective treatment for osteoporosis, improving bone density and reducing fracture incidence.
    • The differing effective doses suggest population-specific pharmacokinetic variations.
    • RSD is a valuable therapeutic option for preventing fractures in osteoporotic individuals, especially the elderly.